IGFBP2 and glioma: The 1-year (AUC=0.877), 2-year (AUC=0.92), 3-year (AUC=0.91), 4-year (AUC=0.858), and 5-year (AUC=0.822) survival ROC curves predicted by IGFBP2 revealed that the AUCs were all higher than 0.8, indicating the efficiency of IGFBP2 in predicting prognosis for glioma (Figures 7E, F).